HAEMALOGIX

haemalogix-logo

Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.HaemaLogiX acquired the business and assets of Immune System Therapeutics Ltd and is embarking on a program of several inter-related projects that will validate antigen targets and products. Two novel drug targets - Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), have been identified on the surface of human blood cancer and autoimmune cells. These targets are highly specific... to abnormal B-cells and have been identified in blood cancers such as multiple myeloma (MM), lymphoma and Waldenstroms macroglobulinemia. Our program will rationally review and pursue opportunities that will deliver a positive proof of the clinical and financial viability of our assets. These opportunities include: validation of antibodies and CAR-T cells; proof of concept for both Kappa and Lambda antigens; and a good understanding of their clinical utility in treating the selected patient populations In pursuing these projects we wish to deliver significant and risk mitigated medium term returns to our investors.

#SimilarOrganizations #People #Financial #Website #More

HAEMALOGIX

Industry:
Biotechnology Health Care Life Science Medical

Address:
Sydney, New South Wales, Australia

Country:
Australia

Website Url:
http://www.haemalogix.com

Total Employee:
1+

Status:
Active

Contact:
+61292094444

Email Addresses:
[email protected]

Total Funding:
10 M AUD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online GStatic Google Static Content Sectigo SSL Sectigo Domain SSL


Similar Organizations

arctic-vision-logo

Arctic Vision

Arctic Vision is focused on the development and commercialization of innovative ophthalmology therapies.

irepertoire-logo

iRepertoire

iRepertoire is to develop and commercialize immune repertoire sequencing technology and products.

myneo-logo

myNEO

myNEO engages in the research, development, and optimization of the clinical exploitability of personalized cancer immunotherapy.

myor-logo

MYOR

MYOR uses skin-surface noninvasive monitoring technologies to adjust nutrition and enable health.

pharmaceutical-biotechnology-logo

Pharmaceutical Biotechnology

Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential.

proteona-logo

Proteona

Proteona develops a genomic and proteomic analysis platform designed for immuno-oncology and immune profiling applications.

reset-pharmaceuticals-logo

Reset Pharmaceuticals

Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments.

scalmibio-logo

ScalmiBio

ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.

senseonics-logo

Senseonics

Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.

Current Employees Featured

not_available_image

Alan Liddle
Alan Liddle Co-Founder & Board Member @ Haemalogix
Co-Founder & Board Member

bryce-carmine_image

Bryce Carmine
Bryce Carmine Co-Founder, Chairman & CEO @ Haemalogix
Co-Founder, Chairman & CEO
2015-03-01

dimitra-korkidas_image

Dimitra Korkidas
Dimitra Korkidas CFO @ Haemalogix
CFO
2015-03-01

professor-mohamad-hussein_image

Professor Mohamad Hussein
Professor Mohamad Hussein Chief Medical Advisor @ Haemalogix
Chief Medical Advisor

Founder


not_available_image

Alan Liddle

bryce-carmine_image

Bryce Carmine

Investors List

platinum-asset-management_image

Platinum Asset Management

Platinum Asset Management investment in Venture Round - Haemalogix

Official Site Inspections

http://www.haemalogix.com

  • Host name: ec2-54-252-156-220.ap-southeast-2.compute.amazonaws.com
  • IP address: 54.252.156.220
  • Location: Sydney Australia
  • Latitude: -33.8591
  • Longitude: 151.2002
  • Timezone: Australia/Sydney
  • Postal: 2000

Loading ...

More informations about "Haemalogix"

HaemaLogiX | Company Overview

HaemaLogiX is a clinical stage Australian biotechnology company, advancing a pipeline of next generation immunotherapies for blood cancers and B-cell disorders. Unlike current therapies, …See details»

Haemalogix - Crunchbase Company Profile & Funding

Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»

HaemaLogiX 2025 Company Profile: Valuation, Funding …

Information on valuation, funding, cap tables, investors, and executives for …See details»

HaemaLogiX - Craft

HaemaLogiX has 5 employees at their 1 location. See insights on HaemaLogiX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»

HaemaLogiX Ltd | LinkedIn

HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research …See details»

Haemalogix - The Org

Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»

HaemaLogiX Pty Ltd. - Drug pipelines, Patents, Clinical trials

Jun 9, 2025 Explore HaemaLogiX Pty Ltd. with its drug pipeline, therapeutic area, technology platform, 8 news, and 1 literature, Disease Domain:Hemic and Lymphatic Diseases ...See details»

Pipeline - Haemalogix

Pipeline HaemaLogiX is engaged in three broad areas of research and development. First, Research & Discovery involves discovering and …See details»

Haemalogix - 2025 Company Profile & Team - Tracxn

Jun 23, 2025 Haemalogix - Developer of immunotherapies for blood cancers and autoimmune diseases. Raised a total funding of $7.47M over 1 round from 3 investors.See details»

HaemaLogiX Ltd - VentureRadar

HaemaLogiX is at the forefront of developing innovative immunotherapies for patients with blood cancers and B-cell disorders. Specializing in monoclonal antibodies, CAR-T cells, and …See details»

HaemaLogiX | Mission & Vision

Our Mission To bring next-generation immunotherapies for multiple myeloma and B cell disorders to market that will transform outcomes by prolonging survival while preserving quality of life for …See details»

Haemalogix - Leadership Team | The Org

The Leadership Team at Haemalogix is responsible for setting the strategic direction of the company, driving innovation in immuno-oncology and immune-therapies, and overseeing …See details»

Info HaemaLogiX - Sydney, New South Wales, Australia - LinkedIn

HaemaLogiX Ltd - development and commercialisation of novel immuno-oncology and immune-therapies · HaemaLogiX focus is the development and commercialisation of novel immuno …See details»

HaemaLogiX | Corporate Governance

At HaemaLogiX, we are committed to maintaining the highest standards of corporate governance to ensure transparency, accountability, and integrity across all aspects of our business. Our …See details»

HaemaLogiX - Startup Galaxy

HaemaLogiX focus is the development and commercialisation of novel immuno-oncology and immune-therapies. HaemaLogiX is embarking on a program of several inter-related research …See details»

Haemalogix - Funding, Financials, Valuation & Investors

Haemalogix focuses on the development and commercialization of novel immuno-oncology and immune-therapies.See details»

HaemaLogix | Board of Directors

Executive Chair Dr John Cullity is Executive Chairman at HaemaLogiX and was a Co-Founder of the Company and has been a Director since the Company's incorporation.See details»

HaemaLogiX Sets the Stage for a $20 Million IPO | Innovation

Apr 7, 2025 HaemaLogiX is preparing for a $20 million IPO in 2025, with groundbreaking innovations like KappaMab and KMA.CAR-T showing promising results in multiple myelomaSee details»

HaemaLogiX | Technology

HaemaLogiX’s immunotherapies bind to unexploited and unique targets (antigens) on the surface of cancerous plasma cells. These antigens are called kappa myeloma antigen (KMA) and …See details»

HaemaLogiX | Latest News

Feb 1, 2024 HaemaLogiX's CMDO, Tertia Dex to speak at the Women in BIO and Health – Industry and Networking Forum HaemaLogiX's CMDO, Tertia Dex will be speaking at the …See details»

linkstock.net © 2022. All rights reserved